

Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is the global association of the world's leading biopharmaceutical companies and national associations. As such, our members are uniquely positioned to help and work in collaboration with WHO, Governments, public health partners, academics, health care professionals and societies to fight the spread of COVID-19. Our thoughts as industry leaders go to all those affected by the illness, and we feel a strong responsibility and solidarity to act in concert, and marshal our people and resources. Individually and collectively, the industry has responded on an unprecedented scale to the pandemic challenge of the novel coronavirus, and we will commit to doing more :

- More than 80 clinical trials are currently underway to test medicines that could treat those infected and help stop spreading the virus, and we are sharing real-time clinical trial data with governments and other companies around the world.
- We are using our investments, expertise and know-how to speed the development of safe and effective vaccines to prevent COVID-19 and partnering with others.
- We are sharing tools and insights to test potential therapies and vaccines as well as developing and scaling up diagnostic tools to allow essential testing for COVID-19 patients.
- We commit to making new treatments and vaccines available to patients and governments at an affordable price.
- We are expanding manufacturing capabilities and are willing to share available capacity to ramp up production once a successful vaccine or treatment is developed.
- Deeply conscious of the importance of continuity of supply for all essential medicines, vaccines, and diagnostics, we are calling on governments and countries for global solidarity and to implement policies and decisions that facilitate access for those in need.